The real world effectiveness and effect on adherence with inhaled asthma therapy of 1 year of Severe Asthma Monoclonal Antibody Treatment

Introduction & Aim: In the UK there are 4 monoclonal antibodies (MAbs) approved to treat severe asthma. We aim to describe the efficacy of these agents in real world clinical practice. Methods: We conducted a retrospective review of pateints who received MAbs for 1 year. Statistical comparisons were carried out on GraphPad Prism v5.0. Continous data (FEV1, number of exacerbations requiring OCS and AQLQ) was compared using a Student’s T test or Man Whitney test following normality testing. Binary data (long term OCS dose & medication prescription collection rate) was compared using Fishers Exact. Results: We assessed 40 patients at 1 year; 52.5% mepolizumab, 22.5% omalizumab, 17.5% benralizumab and 7.5% reslizumab. There was a statistically significant decrease in eosinophil count from 0.6 to 0.09 (p= Conclusion: Clinical trial data for Asthma MAB therapies are borne out in our real world population.